TY  - JOUR
AU  - Micov, Ana
AU  - Tomić, Maja
AU  - Pecikoza, Uroš
AU  - Ugrešić, Nenad
AU  - Stepanović-Petrović, Radica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2435
AB  - Painful diabetic neuropathy is difficult to treat. Single analgesics often have insufficient efficacy and poor tolerability. Combination therapy may therefore be of particular benefit, because it might provide optimal analgesia with fewer adverse effects. This study aimed to examine the type of interaction between levetiracetam, a novel anticonvulsant with analgesic properties, and commonly used analgesics (ibuprofen, aspirin and paracetamol) in a mouse model of painful diabetic neuropathy. Diabetes was induced in C57BL/6 mice with a single high dose of streptozotocin, applied intraperitoneally (150 mg/kg). Thermal (tail-flick test) and mechanical (electronic von Frey test) nociceptive thresholds were measured before and three weeks after diabetes induction. The antinociceptive effects of orally administered levetiracetam, analgesics, and their combinations were examined in diabetic mice that developed thermal/mechanical hypersensitivity. In combination experiments, the drugs were co-administered in fixed-dose fractions of single drug ED50 and the type of interaction was determined by isobolographic analysis. Levetiracetam (10-100 mg/kg), ibuprofen (2-50 mg/kg), aspirin (5-75 mg/kg), paracetamol (5-100 mg/kg), and levetiracetam-analgesic combinations produced significant, dose-dependent antinociceptive effects in diabetic mice in both tests. In the tail-flick test, isobolographic analysis revealed 15-, and 19-fold reduction of doses of both drugs in the combination of levetiracetam with aspirin/ibuprofen, and paracetamol, respectively. In the von Frey test, approximately 7- and 9-fold reduction of doses of both drugs was detected in levetiracetam-ibuprofen and levetiracetam-aspirin/levetiracetam-paracetamol combinations, respectively. These results show synergism between levetiracetam and ibuprofen/aspirin/paracetamol in a model of painful diabetic neuropathy and might provide a useful approach to the treatment of patients suffering from painful diabetic neuropathy.
PB  - Academic Press Ltd- Elsevier Science Ltd, London
T2  - Pharmacological Research
T1  - Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy
VL  - 97
SP  - 131
EP  - 142
DO  - 10.1016/j.phrs.2015.04.014
ER  - 

@article{
author = "Micov, Ana and Tomić, Maja and Pecikoza, Uroš and Ugrešić, Nenad and Stepanović-Petrović, Radica",
year = "2015",
abstract = "Painful diabetic neuropathy is difficult to treat. Single analgesics often have insufficient efficacy and poor tolerability. Combination therapy may therefore be of particular benefit, because it might provide optimal analgesia with fewer adverse effects. This study aimed to examine the type of interaction between levetiracetam, a novel anticonvulsant with analgesic properties, and commonly used analgesics (ibuprofen, aspirin and paracetamol) in a mouse model of painful diabetic neuropathy. Diabetes was induced in C57BL/6 mice with a single high dose of streptozotocin, applied intraperitoneally (150 mg/kg). Thermal (tail-flick test) and mechanical (electronic von Frey test) nociceptive thresholds were measured before and three weeks after diabetes induction. The antinociceptive effects of orally administered levetiracetam, analgesics, and their combinations were examined in diabetic mice that developed thermal/mechanical hypersensitivity. In combination experiments, the drugs were co-administered in fixed-dose fractions of single drug ED50 and the type of interaction was determined by isobolographic analysis. Levetiracetam (10-100 mg/kg), ibuprofen (2-50 mg/kg), aspirin (5-75 mg/kg), paracetamol (5-100 mg/kg), and levetiracetam-analgesic combinations produced significant, dose-dependent antinociceptive effects in diabetic mice in both tests. In the tail-flick test, isobolographic analysis revealed 15-, and 19-fold reduction of doses of both drugs in the combination of levetiracetam with aspirin/ibuprofen, and paracetamol, respectively. In the von Frey test, approximately 7- and 9-fold reduction of doses of both drugs was detected in levetiracetam-ibuprofen and levetiracetam-aspirin/levetiracetam-paracetamol combinations, respectively. These results show synergism between levetiracetam and ibuprofen/aspirin/paracetamol in a model of painful diabetic neuropathy and might provide a useful approach to the treatment of patients suffering from painful diabetic neuropathy.",
publisher = "Academic Press Ltd- Elsevier Science Ltd, London",
journal = "Pharmacological Research",
title = "Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy",
volume = "97",
pages = "131-142",
doi = "10.1016/j.phrs.2015.04.014"
}

Micov, A., Tomić, M., Pecikoza, U., Ugrešić, N.,& Stepanović-Petrović, R.. (2015). Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy. in Pharmacological Research
Academic Press Ltd- Elsevier Science Ltd, London., 97, 131-142.
https://doi.org/10.1016/j.phrs.2015.04.014

Micov A, Tomić M, Pecikoza U, Ugrešić N, Stepanović-Petrović R. Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy. in Pharmacological Research. 2015;97:131-142.
doi:10.1016/j.phrs.2015.04.014 .

Micov, Ana, Tomić, Maja, Pecikoza, Uroš, Ugrešić, Nenad, Stepanović-Petrović, Radica, "Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy" in Pharmacological Research, 97 (2015):131-142,
https://doi.org/10.1016/j.phrs.2015.04.014 . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Vranić, Aleksandra
AU  - Janković, Goran
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2442
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Epicatechin induced vasorelaxation of human internal mammary artery
VL  - 241
IS  - 1
SP  - e50
EP  - e50
DO  - 10.1016/j.atherosclerosis.2015.04.178
ER  - 

@conference{
author = "Novaković, Aleksandra and Marinko, Marija and Vranić, Aleksandra and Janković, Goran and Stojanović, Ivan and Milojević, Predrag and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2015",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Epicatechin induced vasorelaxation of human internal mammary artery",
volume = "241",
number = "1",
pages = "e50-e50",
doi = "10.1016/j.atherosclerosis.2015.04.178"
}

Novaković, A., Marinko, M., Vranić, A., Janković, G., Stojanović, I., Milojević, P., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2015). Epicatechin induced vasorelaxation of human internal mammary artery. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 241(1), e50-e50.
https://doi.org/10.1016/j.atherosclerosis.2015.04.178

Novaković A, Marinko M, Vranić A, Janković G, Stojanović I, Milojević P, Ugrešić N, Kanjuh V, Yang Q, He G. Epicatechin induced vasorelaxation of human internal mammary artery. in Atherosclerosis. 2015;241(1):e50-e50.
doi:10.1016/j.atherosclerosis.2015.04.178 .

Novaković, Aleksandra, Marinko, Marija, Vranić, Aleksandra, Janković, Goran, Stojanović, Ivan, Milojević, Predrag, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Epicatechin induced vasorelaxation of human internal mammary artery" in Atherosclerosis, 241, no. 1 (2015):e50-e50,
https://doi.org/10.1016/j.atherosclerosis.2015.04.178 . .

TY  - JOUR
AU  - Marinko, Marija
AU  - Novaković, Aleksandra
AU  - Nenezić, Dragoslav
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Jović, Miomir
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2461
AB  - As we previously demonstrated the role of different K+ channels in the action of nicorandil on human saphenous vein (HSV) and human internal mammary artery (HIMA), this study aimed to analyse the contribution of the cGMP pathway in nicorandil-induced vasorelaxation and to determine the involvement of cGMP in the K+ channel-activating effect of nicorandil. An inhibitor of soluble guanylate cyclase (GC), ODQ, significantly inhibited nicorandil-induced relaxation, while ODQ plus glibenclamide, a selective ATP-sensitive K+ (KATP) channel inhibitor, produced a further inhibition of both vessels. In HSV, ODQ in combination with 4-aminopyridine, a blocker of voltage-gated K+ (K-V) channels, did not modify the concentration-response to nicorandil compared with ODQ, whereas in HIMA, ODQ plus iberiotoxin, a selective blocker of large-conductance Ca2+-activated K+ (BKCa) channels, produced greater inhibition than ODQ alone. We showed that the cGMP pathway plays a significant role in the vasorelaxant effect of nicorandil on HSV and HIMA. It seems that nicorandil directly opens KATP channels in both vessels and BKCa channels in HIMA, although it is possible that stimulation of GC contributes to KATP channels activation in HIMA. Contrary, the activation of K-V channels in HSV is probably due to GC activation and increased levels of cGMP.
PB  - Japanese Pharmacological Soc, Kyoto
T2  - Journal of Pharmacological Sciences
T1  - Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts
VL  - 128
IS  - 2
SP  - 59
EP  - 64
DO  - 10.1016/j.jphs.2015.03.003
ER  - 

@article{
author = "Marinko, Marija and Novaković, Aleksandra and Nenezić, Dragoslav and Stojanović, Ivan and Milojević, Predrag and Jović, Miomir and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2015",
abstract = "As we previously demonstrated the role of different K+ channels in the action of nicorandil on human saphenous vein (HSV) and human internal mammary artery (HIMA), this study aimed to analyse the contribution of the cGMP pathway in nicorandil-induced vasorelaxation and to determine the involvement of cGMP in the K+ channel-activating effect of nicorandil. An inhibitor of soluble guanylate cyclase (GC), ODQ, significantly inhibited nicorandil-induced relaxation, while ODQ plus glibenclamide, a selective ATP-sensitive K+ (KATP) channel inhibitor, produced a further inhibition of both vessels. In HSV, ODQ in combination with 4-aminopyridine, a blocker of voltage-gated K+ (K-V) channels, did not modify the concentration-response to nicorandil compared with ODQ, whereas in HIMA, ODQ plus iberiotoxin, a selective blocker of large-conductance Ca2+-activated K+ (BKCa) channels, produced greater inhibition than ODQ alone. We showed that the cGMP pathway plays a significant role in the vasorelaxant effect of nicorandil on HSV and HIMA. It seems that nicorandil directly opens KATP channels in both vessels and BKCa channels in HIMA, although it is possible that stimulation of GC contributes to KATP channels activation in HIMA. Contrary, the activation of K-V channels in HSV is probably due to GC activation and increased levels of cGMP.",
publisher = "Japanese Pharmacological Soc, Kyoto",
journal = "Journal of Pharmacological Sciences",
title = "Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts",
volume = "128",
number = "2",
pages = "59-64",
doi = "10.1016/j.jphs.2015.03.003"
}

Marinko, M., Novaković, A., Nenezić, D., Stojanović, I., Milojević, P., Jović, M., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2015). Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts. in Journal of Pharmacological Sciences
Japanese Pharmacological Soc, Kyoto., 128(2), 59-64.
https://doi.org/10.1016/j.jphs.2015.03.003

Marinko M, Novaković A, Nenezić D, Stojanović I, Milojević P, Jović M, Ugrešić N, Kanjuh V, Yang Q, He G. Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts. in Journal of Pharmacological Sciences. 2015;128(2):59-64.
doi:10.1016/j.jphs.2015.03.003 .

Marinko, Marija, Novaković, Aleksandra, Nenezić, Dragoslav, Stojanović, Ivan, Milojević, Predrag, Jović, Miomir, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts" in Journal of Pharmacological Sciences, 128, no. 2 (2015):59-64,
https://doi.org/10.1016/j.jphs.2015.03.003 . .

TY  - JOUR
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Vranić, Aleksandra
AU  - Janković, Goran
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Nenezić, Dragoslav
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2439
AB  - Evidences have suggested that flavanol compound (-)-epicatechin is associated with reduced risk of cardiovascular diseases. One of the mechanisms of its cardioprotective effect is vasodilation. However, the exact mechanisms by which (-)-epicatechin causes vasodilation are not yet clearly defined. The aims of the present study were to investigate relaxant effect of flavanol (-)-epicatechin on the isolated human internal mammary artery (HIMA) and to determine the mechanisms underlying its vasorelaxation. Our results showed that (-)-epicatechin induced a concentration-dependent relaxation of RNA rings pre-contracted by phenylephrine. Among the K+ channel blockers, 4-aminopyricline (4-AP) and margatoxin, blockers of voltage gated K+ (K-V) channels, and glibenclamide, a selective ATP sensitive K+ (K-ATP,) channels blocker, partly inhibited the (-)-epicatechin-induced relaxation of HIMA, while iberiotoxin, a most selective blocker of large conductance Ca2+-activated K+ channels (BKCa), almost completely inhibited the relaxation. In rings pre-contracted by 80 mM K+, (-)-epicatechin induced partial relaxation of HIMA, whereas in Ca2+-free medium, (-)-epicatechin completely relaxed HIMA rings pre-contracted by phenylephrine and caffeine. Finally, thapsigargin, a sarcoplasmic reticulum Ca2+-ATPase inhibitor, slightly antagonized (-)-epicatechin-induced relaxation of HIMA pre-contracted by phenylephrine. These results suggest that (-)-epicatechin induces strong endothelium independent relaxation of HIMA pre-contracted by phenylephrine whilst 4-AP- and rnargatoxin-sensitive K-V channels, as well as BKCa and K-ATP channels, located in vascular smooth muscle, mediate this relaxation. In addition, it seems that (-)-epicatechin could inhibit influx of extracellular Ca2+, interfere with intracellular Ca2+ release and re uptake by the sarcoplasmic reticulum.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmacology
T1  - Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin
VL  - 762
SP  - 306
EP  - 312
DO  - 10.1016/j.ejphar.2015.05.066
ER  - 

@article{
author = "Novaković, Aleksandra and Marinko, Marija and Vranić, Aleksandra and Janković, Goran and Milojević, Predrag and Stojanović, Ivan and Nenezić, Dragoslav and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2015",
abstract = "Evidences have suggested that flavanol compound (-)-epicatechin is associated with reduced risk of cardiovascular diseases. One of the mechanisms of its cardioprotective effect is vasodilation. However, the exact mechanisms by which (-)-epicatechin causes vasodilation are not yet clearly defined. The aims of the present study were to investigate relaxant effect of flavanol (-)-epicatechin on the isolated human internal mammary artery (HIMA) and to determine the mechanisms underlying its vasorelaxation. Our results showed that (-)-epicatechin induced a concentration-dependent relaxation of RNA rings pre-contracted by phenylephrine. Among the K+ channel blockers, 4-aminopyricline (4-AP) and margatoxin, blockers of voltage gated K+ (K-V) channels, and glibenclamide, a selective ATP sensitive K+ (K-ATP,) channels blocker, partly inhibited the (-)-epicatechin-induced relaxation of HIMA, while iberiotoxin, a most selective blocker of large conductance Ca2+-activated K+ channels (BKCa), almost completely inhibited the relaxation. In rings pre-contracted by 80 mM K+, (-)-epicatechin induced partial relaxation of HIMA, whereas in Ca2+-free medium, (-)-epicatechin completely relaxed HIMA rings pre-contracted by phenylephrine and caffeine. Finally, thapsigargin, a sarcoplasmic reticulum Ca2+-ATPase inhibitor, slightly antagonized (-)-epicatechin-induced relaxation of HIMA pre-contracted by phenylephrine. These results suggest that (-)-epicatechin induces strong endothelium independent relaxation of HIMA pre-contracted by phenylephrine whilst 4-AP- and rnargatoxin-sensitive K-V channels, as well as BKCa and K-ATP channels, located in vascular smooth muscle, mediate this relaxation. In addition, it seems that (-)-epicatechin could inhibit influx of extracellular Ca2+, interfere with intracellular Ca2+ release and re uptake by the sarcoplasmic reticulum.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmacology",
title = "Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin",
volume = "762",
pages = "306-312",
doi = "10.1016/j.ejphar.2015.05.066"
}

Novaković, A., Marinko, M., Vranić, A., Janković, G., Milojević, P., Stojanović, I., Nenezić, D., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2015). Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin. in European Journal of Pharmacology
Elsevier Science BV, Amsterdam., 762, 306-312.
https://doi.org/10.1016/j.ejphar.2015.05.066

Novaković A, Marinko M, Vranić A, Janković G, Milojević P, Stojanović I, Nenezić D, Ugrešić N, Kanjuh V, Yang Q, He G. Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin. in European Journal of Pharmacology. 2015;762:306-312.
doi:10.1016/j.ejphar.2015.05.066 .

Novaković, Aleksandra, Marinko, Marija, Vranić, Aleksandra, Janković, Goran, Milojević, Predrag, Stojanović, Ivan, Nenezić, Dragoslav, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Mechanisms underlying the vasorelaxation of human internal mammary artery induced by (-)-epicatechin" in European Journal of Pharmacology, 762 (2015):306-312,
https://doi.org/10.1016/j.ejphar.2015.05.066 . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Vranić, Aleksandra
AU  - Janković, Goran
AU  - Stojanović, Ivan
AU  - Milojević, Predrag
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - Guo-Wei, H.
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2072
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Cardioprotective effect of (-) epicatechin
VL  - 235
IS  - 2
SP  - e111
EP  - e111
DO  - 10.1016/j.atherosclerosis.2014.05.300
ER  - 

@conference{
author = "Novaković, Aleksandra and Vranić, Aleksandra and Janković, Goran and Stojanović, Ivan and Milojević, Predrag and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and Guo-Wei, H.",
year = "2014",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Cardioprotective effect of (-) epicatechin",
volume = "235",
number = "2",
pages = "e111-e111",
doi = "10.1016/j.atherosclerosis.2014.05.300"
}

Novaković, A., Vranić, A., Janković, G., Stojanović, I., Milojević, P., Ugrešić, N., Kanjuh, V., Yang, Q.,& Guo-Wei, H.. (2014). Cardioprotective effect of (-) epicatechin. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 235(2), e111-e111.
https://doi.org/10.1016/j.atherosclerosis.2014.05.300

Novaković A, Vranić A, Janković G, Stojanović I, Milojević P, Ugrešić N, Kanjuh V, Yang Q, Guo-Wei H. Cardioprotective effect of (-) epicatechin. in Atherosclerosis. 2014;235(2):e111-e111.
doi:10.1016/j.atherosclerosis.2014.05.300 .

Novaković, Aleksandra, Vranić, Aleksandra, Janković, Goran, Stojanović, Ivan, Milojević, Predrag, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, Guo-Wei, H., "Cardioprotective effect of (-) epicatechin" in Atherosclerosis, 235, no. 2 (2014):e111-e111,
https://doi.org/10.1016/j.atherosclerosis.2014.05.300 . .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Marinko, Marija
AU  - Milojević, Predrag
AU  - Babić, Milan
AU  - Stojanović, Ivan
AU  - Jović, Miomir
AU  - Nenezić, Dragoslav
AU  - Ugrešić, Nenad
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1728
PB  - Lippincott Williams & Wilkins, Philadelphia
C3  - Circulation
T1  - Relaxation of arterial graft induced by nicorandil
VL  - 125
IS  - 19
SP  - e184
EP  - e184
DO  - 10.1161/CIR.0b013e31824fcdb3
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1728
ER  - 

@conference{
author = "Novaković, Aleksandra and Marinko, Marija and Milojević, Predrag and Babić, Milan and Stojanović, Ivan and Jović, Miomir and Nenezić, Dragoslav and Ugrešić, Nenad and Yang, Qin and He, Guo-Wei",
year = "2012",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Circulation",
title = "Relaxation of arterial graft induced by nicorandil",
volume = "125",
number = "19",
pages = "e184-e184",
doi = "10.1161/CIR.0b013e31824fcdb3",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1728"
}

Novaković, A., Marinko, M., Milojević, P., Babić, M., Stojanović, I., Jović, M., Nenezić, D., Ugrešić, N., Yang, Q.,& He, G.. (2012). Relaxation of arterial graft induced by nicorandil. in Circulation
Lippincott Williams & Wilkins, Philadelphia., 125(19), e184-e184.
https://doi.org/10.1161/CIR.0b013e31824fcdb3
https://hdl.handle.net/21.15107/rcub_farfar_1728

Novaković A, Marinko M, Milojević P, Babić M, Stojanović I, Jović M, Nenezić D, Ugrešić N, Yang Q, He G. Relaxation of arterial graft induced by nicorandil. in Circulation. 2012;125(19):e184-e184.
doi:10.1161/CIR.0b013e31824fcdb3
https://hdl.handle.net/21.15107/rcub_farfar_1728 .

Novaković, Aleksandra, Marinko, Marija, Milojević, Predrag, Babić, Milan, Stojanović, Ivan, Jović, Miomir, Nenezić, Dragoslav, Ugrešić, Nenad, Yang, Qin, He, Guo-Wei, "Relaxation of arterial graft induced by nicorandil" in Circulation, 125, no. 19 (2012):e184-e184,
https://doi.org/10.1161/CIR.0b013e31824fcdb3 .,
https://hdl.handle.net/21.15107/rcub_farfar_1728 .

TY  - CONF
AU  - Novaković, Aleksandra
AU  - Pavlović, M.
AU  - Vranić, Aleksandra
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Jović, M.
AU  - Nenezić, Dragoslav
AU  - Ugrešić, Nenad
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1702
PB  - Oxford Univ Press, Oxford
C3  - Cardiovascular Research
T1  - Different potassium channels are involved in relaxation of arterial graft induced by nicorandil
VL  - 93
DO  - 10.1093/cvr/cvr332
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1702
ER  - 

@conference{
author = "Novaković, Aleksandra and Pavlović, M. and Vranić, Aleksandra and Milojević, Predrag and Stojanović, Ivan and Jović, M. and Nenezić, Dragoslav and Ugrešić, Nenad and Yang, Qin and He, Guo-Wei",
year = "2012",
publisher = "Oxford Univ Press, Oxford",
journal = "Cardiovascular Research",
title = "Different potassium channels are involved in relaxation of arterial graft induced by nicorandil",
volume = "93",
doi = "10.1093/cvr/cvr332",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1702"
}

Novaković, A., Pavlović, M., Vranić, A., Milojević, P., Stojanović, I., Jović, M., Nenezić, D., Ugrešić, N., Yang, Q.,& He, G.. (2012). Different potassium channels are involved in relaxation of arterial graft induced by nicorandil. in Cardiovascular Research
Oxford Univ Press, Oxford., 93.
https://doi.org/10.1093/cvr/cvr332
https://hdl.handle.net/21.15107/rcub_farfar_1702

Novaković A, Pavlović M, Vranić A, Milojević P, Stojanović I, Jović M, Nenezić D, Ugrešić N, Yang Q, He G. Different potassium channels are involved in relaxation of arterial graft induced by nicorandil. in Cardiovascular Research. 2012;93.
doi:10.1093/cvr/cvr332
https://hdl.handle.net/21.15107/rcub_farfar_1702 .

Novaković, Aleksandra, Pavlović, M., Vranić, Aleksandra, Milojević, Predrag, Stojanović, Ivan, Jović, M., Nenezić, Dragoslav, Ugrešić, Nenad, Yang, Qin, He, Guo-Wei, "Different potassium channels are involved in relaxation of arterial graft induced by nicorandil" in Cardiovascular Research, 93 (2012),
https://doi.org/10.1093/cvr/cvr332 .,
https://hdl.handle.net/21.15107/rcub_farfar_1702 .

TY  - JOUR
AU  - Stepanović-Petrović, Radica
AU  - Micov, Ana
AU  - Tomić, Maja
AU  - Ugrešić, Nenad
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1679
AB  - BACKGROUND: We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/antiedematous effects in the same model of localized inflammation and whether opioidergic, adrenergic, purinergic, 5-HTergic, and GABAergic receptors are involved in its antihyperalgesic action. METHODS: Rats were intraplantarly (IPL) injected with carrageenan. A paw pressure test was used to determine the effect/s of (a) levetiracetam when applied IPL, on carrageenan-induced hyperalgesia, and (b) naloxone (a nonselective opioid receptor antagonist), CTAP (a selective mu-opioid receptor antagonist); yohimbine (a selective alpha(2)-adrenoceptor antagonist), BRL 44408 (a selective alpha(2A)-adrenoceptor antagonist), MK-912 (a selective alpha(2C)-adrenoceptor antagonist); caffeine (a nonselective adenosine receptor antagonist), DPCPX (a selective adenosine A(1) receptor antagonist); methysergide (a nonselective 5-HT receptor antagonist), GR 127935 (a selective 5-HT1B/1D receptor antagonist); and bicuculline (a selective GABA(A) receptor antagonist), all applied IPL, on the levetiracetam-induced antihyperalgesia. Moreover, levetiracetam's influence on paw inflammatory edema was measured by plethysmometry. RESULTS: Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan. Naloxone (75-300 nmol/paw), CTAP (1-5 nmol/paw); yohimbine (130-520 nmol/paw), BRL 44408 (50-200 nmol/paw), MK-912 (5-20 nmol/paw); caffeine (500-1500 nmol/paw), DPCPX (3-30 nmol/paw); methysergide (10-100 nmol/paw) and GR 127935 (50-200 nmol/paw); but not bicuculline (400 nmol/paw), significantly depressed the antihyperalgesic effects of levetiracetam (1000 nmol/paw). The effects of levetiracetam and antagonists were attributed to local peripheral effects because they were not observed after administration into the contralateral hindpaw. CONCLUSIONS: Our results show that levetiracetam produces local peripheral antihyperalgesic and antiedematous effects in a rat model of localized inflammation. Antihyperalgesia is at least in part mediated by peripheral mu-opioid, alpha(2A,C)-adrenergic, A(1) adenosine, and 5-HT1B/1D receptors, but not by GABA(A) receptors. These findings could contribute toward a better understanding of the analgesic effects of levetiracetam, and improved treatments of inflammatory pain with a lower incidence of systemic side effects and drug interactions of levetiracetam. (Anesth Analg, 2012;115:1457-66)
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Anesthesia and Analgesia
T1  - The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model
VL  - 115
IS  - 6
SP  - 1457
EP  - 1466
DO  - 10.1213/ANE.0b013e31826c7fc2
ER  - 

@article{
author = "Stepanović-Petrović, Radica and Micov, Ana and Tomić, Maja and Ugrešić, Nenad",
year = "2012",
abstract = "BACKGROUND: We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/antiedematous effects in the same model of localized inflammation and whether opioidergic, adrenergic, purinergic, 5-HTergic, and GABAergic receptors are involved in its antihyperalgesic action. METHODS: Rats were intraplantarly (IPL) injected with carrageenan. A paw pressure test was used to determine the effect/s of (a) levetiracetam when applied IPL, on carrageenan-induced hyperalgesia, and (b) naloxone (a nonselective opioid receptor antagonist), CTAP (a selective mu-opioid receptor antagonist); yohimbine (a selective alpha(2)-adrenoceptor antagonist), BRL 44408 (a selective alpha(2A)-adrenoceptor antagonist), MK-912 (a selective alpha(2C)-adrenoceptor antagonist); caffeine (a nonselective adenosine receptor antagonist), DPCPX (a selective adenosine A(1) receptor antagonist); methysergide (a nonselective 5-HT receptor antagonist), GR 127935 (a selective 5-HT1B/1D receptor antagonist); and bicuculline (a selective GABA(A) receptor antagonist), all applied IPL, on the levetiracetam-induced antihyperalgesia. Moreover, levetiracetam's influence on paw inflammatory edema was measured by plethysmometry. RESULTS: Levetiracetam (200-1000 nmol/paw) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia and edema induced by carrageenan. Naloxone (75-300 nmol/paw), CTAP (1-5 nmol/paw); yohimbine (130-520 nmol/paw), BRL 44408 (50-200 nmol/paw), MK-912 (5-20 nmol/paw); caffeine (500-1500 nmol/paw), DPCPX (3-30 nmol/paw); methysergide (10-100 nmol/paw) and GR 127935 (50-200 nmol/paw); but not bicuculline (400 nmol/paw), significantly depressed the antihyperalgesic effects of levetiracetam (1000 nmol/paw). The effects of levetiracetam and antagonists were attributed to local peripheral effects because they were not observed after administration into the contralateral hindpaw. CONCLUSIONS: Our results show that levetiracetam produces local peripheral antihyperalgesic and antiedematous effects in a rat model of localized inflammation. Antihyperalgesia is at least in part mediated by peripheral mu-opioid, alpha(2A,C)-adrenergic, A(1) adenosine, and 5-HT1B/1D receptors, but not by GABA(A) receptors. These findings could contribute toward a better understanding of the analgesic effects of levetiracetam, and improved treatments of inflammatory pain with a lower incidence of systemic side effects and drug interactions of levetiracetam. (Anesth Analg, 2012;115:1457-66)",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Anesthesia and Analgesia",
title = "The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model",
volume = "115",
number = "6",
pages = "1457-1466",
doi = "10.1213/ANE.0b013e31826c7fc2"
}

Stepanović-Petrović, R., Micov, A., Tomić, M.,& Ugrešić, N.. (2012). The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model. in Anesthesia and Analgesia
Lippincott Williams & Wilkins, Philadelphia., 115(6), 1457-1466.
https://doi.org/10.1213/ANE.0b013e31826c7fc2

Stepanović-Petrović R, Micov A, Tomić M, Ugrešić N. The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model. in Anesthesia and Analgesia. 2012;115(6):1457-1466.
doi:10.1213/ANE.0b013e31826c7fc2 .

Stepanović-Petrović, Radica, Micov, Ana, Tomić, Maja, Ugrešić, Nenad, "The Local Peripheral Antihyperalgesic Effect of Levetiracetam and Its Mechanism of Action in an Inflammatory Pain Model" in Anesthesia and Analgesia, 115, no. 6 (2012):1457-1466,
https://doi.org/10.1213/ANE.0b013e31826c7fc2 . .

TY  - JOUR
AU  - Novaković, Aleksandra
AU  - Pavlović, Marija
AU  - Milojević, Predrag
AU  - Stojanović, Ivan
AU  - Nenezić, Dragoslav
AU  - Jović, Miomir
AU  - Ugrešić, Nenad
AU  - Kanjuh, Vladimir
AU  - Yang, Qin
AU  - He, Guo-Wei
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1731
AB  - The ATP-sensitive K+ channels opener (KATPCO), P1075 [N-cyano-N'-(1,1-dimethylpropyl)-N?-3-pyridylguanidine], has been shown to cause relaxation of various isolated animal and human blood vessels by opening of vascular smooth muscle ATP-sensitive K+ (KATP) channels. In addition to the well-known effect on the opening of KATP channels, it has been reported that vasorelaxation induced by some of the KATPCOs includes some other K+ channel subtypes. Given that there is still no information on other types of K+ channels possibly involved in the mechanism of relaxation induced by P1075, this study was designed to examine the effects of P1075 on the rat renal artery with endothelium and with denuded endothelium and to define the contribution of different K+ channel subtypes in the P1075 action on this blood vessel. Our results show that P1075 induced a concentration-dependent relaxation of rat renal artery rings pre-contracted by phenylephrine. Glibenclamide, a selective KATP channels inhibitor, partly antagonized the relaxation of rat renal artery induced by P1075. Tetraethylammonium (TEA), a non-selective inhibitor of Ca2+-activated K+ channels, as well as iberiotoxin, a most selective blocker of large-conductance Ca2+-activated K+ (BKCa) channels, did not abolish the effect of P1075 on rat renal artery. In contrast, a non-selective blocker of voltage-gated K+ (KV) channels, 4-aminopyridine (4-AP), as well as margatoxin, a potent inhibitor of KV1.3 channels, caused partial inhibition of the P1075-induced relaxation of rat renal artery. In addition, in this study, P1075 relaxed contractions induced by 20 similar to mM K+, but had no effect on contractions induced by 80 similar to mM K+. Our results showed that P1075 induced strong endothelium-independent relaxation of rat renal artery. It seems that KATP, 4-AP- and margatoxin-sensitive K+ channels located in vascular smooth muscle mediated the relaxation of rat renal artery induced by P1075.
PB  - Wiley, Hoboken
T2  - Basic & Clinical Pharmacology & Toxicology
T1  - Different Potassium Channels are Involved in Relaxation of Rat Renal Artery Induced by P1075
VL  - 111
IS  - 1
SP  - 24
EP  - 30
DO  - 10.1111/j.1742-7843.2011.00855.x
ER  - 

@article{
author = "Novaković, Aleksandra and Pavlović, Marija and Milojević, Predrag and Stojanović, Ivan and Nenezić, Dragoslav and Jović, Miomir and Ugrešić, Nenad and Kanjuh, Vladimir and Yang, Qin and He, Guo-Wei",
year = "2012",
abstract = "The ATP-sensitive K+ channels opener (KATPCO), P1075 [N-cyano-N'-(1,1-dimethylpropyl)-N?-3-pyridylguanidine], has been shown to cause relaxation of various isolated animal and human blood vessels by opening of vascular smooth muscle ATP-sensitive K+ (KATP) channels. In addition to the well-known effect on the opening of KATP channels, it has been reported that vasorelaxation induced by some of the KATPCOs includes some other K+ channel subtypes. Given that there is still no information on other types of K+ channels possibly involved in the mechanism of relaxation induced by P1075, this study was designed to examine the effects of P1075 on the rat renal artery with endothelium and with denuded endothelium and to define the contribution of different K+ channel subtypes in the P1075 action on this blood vessel. Our results show that P1075 induced a concentration-dependent relaxation of rat renal artery rings pre-contracted by phenylephrine. Glibenclamide, a selective KATP channels inhibitor, partly antagonized the relaxation of rat renal artery induced by P1075. Tetraethylammonium (TEA), a non-selective inhibitor of Ca2+-activated K+ channels, as well as iberiotoxin, a most selective blocker of large-conductance Ca2+-activated K+ (BKCa) channels, did not abolish the effect of P1075 on rat renal artery. In contrast, a non-selective blocker of voltage-gated K+ (KV) channels, 4-aminopyridine (4-AP), as well as margatoxin, a potent inhibitor of KV1.3 channels, caused partial inhibition of the P1075-induced relaxation of rat renal artery. In addition, in this study, P1075 relaxed contractions induced by 20 similar to mM K+, but had no effect on contractions induced by 80 similar to mM K+. Our results showed that P1075 induced strong endothelium-independent relaxation of rat renal artery. It seems that KATP, 4-AP- and margatoxin-sensitive K+ channels located in vascular smooth muscle mediated the relaxation of rat renal artery induced by P1075.",
publisher = "Wiley, Hoboken",
journal = "Basic & Clinical Pharmacology & Toxicology",
title = "Different Potassium Channels are Involved in Relaxation of Rat Renal Artery Induced by P1075",
volume = "111",
number = "1",
pages = "24-30",
doi = "10.1111/j.1742-7843.2011.00855.x"
}

Novaković, A., Pavlović, M., Milojević, P., Stojanović, I., Nenezić, D., Jović, M., Ugrešić, N., Kanjuh, V., Yang, Q.,& He, G.. (2012). Different Potassium Channels are Involved in Relaxation of Rat Renal Artery Induced by P1075. in Basic & Clinical Pharmacology & Toxicology
Wiley, Hoboken., 111(1), 24-30.
https://doi.org/10.1111/j.1742-7843.2011.00855.x

Novaković A, Pavlović M, Milojević P, Stojanović I, Nenezić D, Jović M, Ugrešić N, Kanjuh V, Yang Q, He G. Different Potassium Channels are Involved in Relaxation of Rat Renal Artery Induced by P1075. in Basic & Clinical Pharmacology & Toxicology. 2012;111(1):24-30.
doi:10.1111/j.1742-7843.2011.00855.x .

Novaković, Aleksandra, Pavlović, Marija, Milojević, Predrag, Stojanović, Ivan, Nenezić, Dragoslav, Jović, Miomir, Ugrešić, Nenad, Kanjuh, Vladimir, Yang, Qin, He, Guo-Wei, "Different Potassium Channels are Involved in Relaxation of Rat Renal Artery Induced by P1075" in Basic & Clinical Pharmacology & Toxicology, 111, no. 1 (2012):24-30,
https://doi.org/10.1111/j.1742-7843.2011.00855.x . .

TY  - JOUR
AU  - Marinko, Marija
AU  - Ugrešić, Nenad
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1598
AB  - Insulin is anabolic and anti-catabolic hormone which has an important role in the metabolism of carbohydrates, proteins and lipids. In addition, insulin is the only agent used in all forms of diabetes mellitus for blood sugar control. Further, insulin is critical for the management of diabetic ketoacidosis, and it has an important role in the treatment of hyperglycemic, nonketotic coma and in the perioperative management of diabetic patients. Commercial insulin preparations, used today, represent result of recombinant DNA technology and have amino acid sequence identical to human insulin. Also, insulin analogs are produced by modifications in insulin molecule in order to improve pharmacokinetic properties. In this article, insulin preparations are described including their classification, characteristics and safety of use in a pregnancy.
AB  - Insulin je anabolički i antikatabolički hormon koji ima važnu ulogu u metabolizmu ugljenih hidrata, proteina i masti. Insulin je jedino sredstvo koje se koristi za kontrolu nivoa glukoze u krvi kod svih oblika dijabetes melitusa. Osim toga, važan je u terapiji dijabetesne ketoacidoze i ima značajnu ulogu u lečenju hiperglikemijske, hiperosmolarne, neketonske kome, kao i u perioperativnom tretmanu bolesnika sa dijabetesom. Preparati insulina koji se koriste u današnje vreme su rezultat rekombinantne DNK tehnologije i sadrže sekvencu aminokiselina identičnu humanom insulinu. Takođe, modifikacijama u molekulu insulina dobijeni su insulinski analozi sa ciljem poboljšavanja farmakokinetičkih osobina. U ovom radu su opisani preparati insulina, njihova podela, osnovne karakteristike i bezbednost primene u trudnoći.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Pharmacology of insulin
T1  - Farmakologija insulina
VL  - 61
IS  - 4
SP  - 383
EP  - 392
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1598
ER  - 

@article{
author = "Marinko, Marija and Ugrešić, Nenad",
year = "2011",
abstract = "Insulin is anabolic and anti-catabolic hormone which has an important role in the metabolism of carbohydrates, proteins and lipids. In addition, insulin is the only agent used in all forms of diabetes mellitus for blood sugar control. Further, insulin is critical for the management of diabetic ketoacidosis, and it has an important role in the treatment of hyperglycemic, nonketotic coma and in the perioperative management of diabetic patients. Commercial insulin preparations, used today, represent result of recombinant DNA technology and have amino acid sequence identical to human insulin. Also, insulin analogs are produced by modifications in insulin molecule in order to improve pharmacokinetic properties. In this article, insulin preparations are described including their classification, characteristics and safety of use in a pregnancy., Insulin je anabolički i antikatabolički hormon koji ima važnu ulogu u metabolizmu ugljenih hidrata, proteina i masti. Insulin je jedino sredstvo koje se koristi za kontrolu nivoa glukoze u krvi kod svih oblika dijabetes melitusa. Osim toga, važan je u terapiji dijabetesne ketoacidoze i ima značajnu ulogu u lečenju hiperglikemijske, hiperosmolarne, neketonske kome, kao i u perioperativnom tretmanu bolesnika sa dijabetesom. Preparati insulina koji se koriste u današnje vreme su rezultat rekombinantne DNK tehnologije i sadrže sekvencu aminokiselina identičnu humanom insulinu. Takođe, modifikacijama u molekulu insulina dobijeni su insulinski analozi sa ciljem poboljšavanja farmakokinetičkih osobina. U ovom radu su opisani preparati insulina, njihova podela, osnovne karakteristike i bezbednost primene u trudnoći.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Pharmacology of insulin, Farmakologija insulina",
volume = "61",
number = "4",
pages = "383-392",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1598"
}

Marinko, M.,& Ugrešić, N.. (2011). Pharmacology of insulin. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 61(4), 383-392.
https://hdl.handle.net/21.15107/rcub_farfar_1598

Marinko M, Ugrešić N. Pharmacology of insulin. in Arhiv za farmaciju. 2011;61(4):383-392.
https://hdl.handle.net/21.15107/rcub_farfar_1598 .

Marinko, Marija, Ugrešić, Nenad, "Pharmacology of insulin" in Arhiv za farmaciju, 61, no. 4 (2011):383-392,
https://hdl.handle.net/21.15107/rcub_farfar_1598 .

TY  - JOUR
AU  - Stepanović-Petrović, Radica
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Poznanović, Goran
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1537
AB  - Oxcarbazepine, ibuprofen and etodolac have efficacy in inflammatory pain. The combination of different drugs activates both central and peripheral pain inhibitory pathways to induce additive or synergistic antinociception, and this interaction may allow lower doses of each drug combined and improve the safety profile, with lower side-effects. This study aimed to examine the effects of oxcarbazepine-ibuprofen and oxcarbazepine-etodolac combinations, in a rat model of inflammatory hyperalgesia, and determine the type of interaction between drugs. Rats were intraplantarly injected with carrageenan (0.1 ml, 1%) and the hyperalgesia was assessed by modified paw pressure test. The anti-hyperalgesic effects of oxcarbazepine, ibuprofen and etodolac and oxcarbazepinei-buprofen and oxcarbazepine-etodolac combinations were examined. Drugs were co-administered in a fixed-dose fractions of the ED(50) and the type of interaction was determined by isobolographic analysis. Oxcarbazepine (40-160 mg/kg; p.o.), ibuprofen (10-120 mg/kg; p.o.) and etodolac (5-20 mg/kg; p.o.) produced a significant, dose-dependent anti-hyperalgesia in carrageenan-injected rats. ED(50) values (mean +/- SEM) for oxcarbazepine, ibuprofen and etodolac were 88.17 +/- 3.65, 47.07 +/- 10.27 and 13.05 +/- 1.42 mg/kg, respectively. Oxcarbazepine-ibuprofen and oxcarbazepine-etodolac combinations induced significant and dose-dependent anti-hyperalgesia. lsobolographic analysis revealed that oxcarbazepine exerts a synergistic interaction with ibuprofen, with almost 4-fold reduction of doses of both drugs in combination. In contrast, there was an additive interaction with etodolac. Synergistic interaction of oxcarbazepine with ibuprofen and its additive interaction with etodolac provide new information about the combination pain treatment and could be explored further in patients with inflammatory pain. Adverse effect analysis of the combinations is necessary to verify possible clinical use of the mixtures.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Pharmacology Biochemistry and Behavior
T1  - Pharmacological interaction between oxcarbazepine and two COX inhibitors in a rat model of inflammatory hyperalgesia
VL  - 97
IS  - 3
SP  - 611
EP  - 618
DO  - 10.1016/j.pbb.2010.11.007
ER  - 

@article{
author = "Stepanović-Petrović, Radica and Tomić, Maja and Vučković, Sonja M. and Poznanović, Goran and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2011",
abstract = "Oxcarbazepine, ibuprofen and etodolac have efficacy in inflammatory pain. The combination of different drugs activates both central and peripheral pain inhibitory pathways to induce additive or synergistic antinociception, and this interaction may allow lower doses of each drug combined and improve the safety profile, with lower side-effects. This study aimed to examine the effects of oxcarbazepine-ibuprofen and oxcarbazepine-etodolac combinations, in a rat model of inflammatory hyperalgesia, and determine the type of interaction between drugs. Rats were intraplantarly injected with carrageenan (0.1 ml, 1%) and the hyperalgesia was assessed by modified paw pressure test. The anti-hyperalgesic effects of oxcarbazepine, ibuprofen and etodolac and oxcarbazepinei-buprofen and oxcarbazepine-etodolac combinations were examined. Drugs were co-administered in a fixed-dose fractions of the ED(50) and the type of interaction was determined by isobolographic analysis. Oxcarbazepine (40-160 mg/kg; p.o.), ibuprofen (10-120 mg/kg; p.o.) and etodolac (5-20 mg/kg; p.o.) produced a significant, dose-dependent anti-hyperalgesia in carrageenan-injected rats. ED(50) values (mean +/- SEM) for oxcarbazepine, ibuprofen and etodolac were 88.17 +/- 3.65, 47.07 +/- 10.27 and 13.05 +/- 1.42 mg/kg, respectively. Oxcarbazepine-ibuprofen and oxcarbazepine-etodolac combinations induced significant and dose-dependent anti-hyperalgesia. lsobolographic analysis revealed that oxcarbazepine exerts a synergistic interaction with ibuprofen, with almost 4-fold reduction of doses of both drugs in combination. In contrast, there was an additive interaction with etodolac. Synergistic interaction of oxcarbazepine with ibuprofen and its additive interaction with etodolac provide new information about the combination pain treatment and could be explored further in patients with inflammatory pain. Adverse effect analysis of the combinations is necessary to verify possible clinical use of the mixtures.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Pharmacology Biochemistry and Behavior",
title = "Pharmacological interaction between oxcarbazepine and two COX inhibitors in a rat model of inflammatory hyperalgesia",
volume = "97",
number = "3",
pages = "611-618",
doi = "10.1016/j.pbb.2010.11.007"
}

Stepanović-Petrović, R., Tomić, M., Vučković, S. M., Poznanović, G., Ugrešić, N., Prostran, M.,& Bošković, B.. (2011). Pharmacological interaction between oxcarbazepine and two COX inhibitors in a rat model of inflammatory hyperalgesia. in Pharmacology Biochemistry and Behavior
Pergamon-Elsevier Science Ltd, Oxford., 97(3), 611-618.
https://doi.org/10.1016/j.pbb.2010.11.007

Stepanović-Petrović R, Tomić M, Vučković SM, Poznanović G, Ugrešić N, Prostran M, Bošković B. Pharmacological interaction between oxcarbazepine and two COX inhibitors in a rat model of inflammatory hyperalgesia. in Pharmacology Biochemistry and Behavior. 2011;97(3):611-618.
doi:10.1016/j.pbb.2010.11.007 .

Stepanović-Petrović, Radica, Tomić, Maja, Vučković, Sonja M., Poznanović, Goran, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Pharmacological interaction between oxcarbazepine and two COX inhibitors in a rat model of inflammatory hyperalgesia" in Pharmacology Biochemistry and Behavior, 97, no. 3 (2011):611-618,
https://doi.org/10.1016/j.pbb.2010.11.007 . .

TY  - JOUR
AU  - Savić, Miroslav
AU  - Ugrešić, Nenad
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1608
AB  - Acute upper respiratory tract viral infections are frequently manifested through the common cold and influenza, a mainly mild and a potentially life-threatening clinical syndrome, respectively. Cough and fever (>37.8 °C) in an influenza-like illness, especially in the context of an influenza epidemic, suggest the existence of an influenza syndrome. While the available treatments against the common cold are purely symptomatic (alleviation of sore throat, sneezing, rhinorrhoea, nasal congestion, watery eyes, cough, headache, chilliness and fever), the annual seasonal trivalent vaccine and neuraminidase inhibitors are usually effective measures against influenza. It is hypothesized that frequent colds may reduce the likelihood of infection with influenza and hence be protective. In this vein, the complete prevention may be worse than the inconvenience due to illness and it seems reasonable to try and reduce the public health burden of common cold, but surely not eliminate the common colds altogether. In regard to the influenza, the epidemiological experience warn us that the generally positive results of prophylactic and therapeutic measures during the last pandemic (2009-2010) do not preclude the appearance of some newer genetic reassortments of the virus in the future, possibly threatening the whole population.
AB  - Virusne infekcije gornjih disajnih puteva često se manifestuju kao klinički sindromi prehlade (uglavnom blagi), odnosno gripa (potencijalno životno ugrožavajući). Kašalj i groznica (temperatura >37,8 °C) u gripu-sličnom stanju, posebno u uslovima proglašene epidemije gripa, sugerišu postojanje sindroma gripa. Dok su dostupni tretmani protiv prehlade čisto simptomatski (ublažavanje gušobolje, kijanja, curenja nosa, kongestije nosa, suzenja očiju, kašlja, glavobolje, jeze i groznice), godišnja 'sezonska' trovalentna vakcina i inhibitori neuraminidaze su obično efektivne profilaktičke, odnosno terapijske mere protiv gripa. Postavljena je hipoteza da česte prehlade mogu da smanje verovatnoću infekcije virusom gripa i da stoga mogu da imaju zaštitnu ulogu. U tom smislu, potpuna prevencija prehlada bi mogla da ima lošije posledice od neprijatnosti usled same bolesti. Stoga, mere smanjenja opterećenja za javno zdravlje koje nose prehlade jesu potrebne, ali se ne čini racionalnim eventualno eliminisanje prehlade uopšte. U odnosu na grip, epidemiološko iskustvo nas upozorava da generalno pozitivni rezultati profilaktičkih i terapijskih mera tokom poslednje pandemije (2009-2010) ne isključuju mogućnost pojave nekih novih genetskih resortiranja virusa u budućnosti, koja bi mogla da ugroze celu populaciju.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Pharmacotherapy of the common cold and influenza
T1  - Farmakoterapija prehlade i gripa
VL  - 61
IS  - 2
SP  - 152
EP  - 164
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1608
ER  - 

@article{
author = "Savić, Miroslav and Ugrešić, Nenad",
year = "2011",
abstract = "Acute upper respiratory tract viral infections are frequently manifested through the common cold and influenza, a mainly mild and a potentially life-threatening clinical syndrome, respectively. Cough and fever (>37.8 °C) in an influenza-like illness, especially in the context of an influenza epidemic, suggest the existence of an influenza syndrome. While the available treatments against the common cold are purely symptomatic (alleviation of sore throat, sneezing, rhinorrhoea, nasal congestion, watery eyes, cough, headache, chilliness and fever), the annual seasonal trivalent vaccine and neuraminidase inhibitors are usually effective measures against influenza. It is hypothesized that frequent colds may reduce the likelihood of infection with influenza and hence be protective. In this vein, the complete prevention may be worse than the inconvenience due to illness and it seems reasonable to try and reduce the public health burden of common cold, but surely not eliminate the common colds altogether. In regard to the influenza, the epidemiological experience warn us that the generally positive results of prophylactic and therapeutic measures during the last pandemic (2009-2010) do not preclude the appearance of some newer genetic reassortments of the virus in the future, possibly threatening the whole population., Virusne infekcije gornjih disajnih puteva često se manifestuju kao klinički sindromi prehlade (uglavnom blagi), odnosno gripa (potencijalno životno ugrožavajući). Kašalj i groznica (temperatura >37,8 °C) u gripu-sličnom stanju, posebno u uslovima proglašene epidemije gripa, sugerišu postojanje sindroma gripa. Dok su dostupni tretmani protiv prehlade čisto simptomatski (ublažavanje gušobolje, kijanja, curenja nosa, kongestije nosa, suzenja očiju, kašlja, glavobolje, jeze i groznice), godišnja 'sezonska' trovalentna vakcina i inhibitori neuraminidaze su obično efektivne profilaktičke, odnosno terapijske mere protiv gripa. Postavljena je hipoteza da česte prehlade mogu da smanje verovatnoću infekcije virusom gripa i da stoga mogu da imaju zaštitnu ulogu. U tom smislu, potpuna prevencija prehlada bi mogla da ima lošije posledice od neprijatnosti usled same bolesti. Stoga, mere smanjenja opterećenja za javno zdravlje koje nose prehlade jesu potrebne, ali se ne čini racionalnim eventualno eliminisanje prehlade uopšte. U odnosu na grip, epidemiološko iskustvo nas upozorava da generalno pozitivni rezultati profilaktičkih i terapijskih mera tokom poslednje pandemije (2009-2010) ne isključuju mogućnost pojave nekih novih genetskih resortiranja virusa u budućnosti, koja bi mogla da ugroze celu populaciju.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Pharmacotherapy of the common cold and influenza, Farmakoterapija prehlade i gripa",
volume = "61",
number = "2",
pages = "152-164",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1608"
}

Savić, M.,& Ugrešić, N.. (2011). Pharmacotherapy of the common cold and influenza. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 61(2), 152-164.
https://hdl.handle.net/21.15107/rcub_farfar_1608

Savić M, Ugrešić N. Pharmacotherapy of the common cold and influenza. in Arhiv za farmaciju. 2011;61(2):152-164.
https://hdl.handle.net/21.15107/rcub_farfar_1608 .

Savić, Miroslav, Ugrešić, Nenad, "Pharmacotherapy of the common cold and influenza" in Arhiv za farmaciju, 61, no. 2 (2011):152-164,
https://hdl.handle.net/21.15107/rcub_farfar_1608 .

TY  - JOUR
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Stepanović-Petrović, Radica
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1375
AB  - BACKGROUND: Combination therapy is a valid approach in pain treatment, in which a reduction of doses could reduce side effects and still achieve optimal analgesia. We examined the effects of coadministered paracetamol, a widely used non-opioid analgesic, and oxcarbazepine, a relatively novel anticonvulsant with analgesic properties, in a rat model of paw inflammatory hyperalgesia and in a mice model of visceral pain and determined the type of interaction between components. METHODS: The effects of paracetamol, oxcarbazepine, and their combinations were examined in carrageenan-induced (0.1 mL, 1%) paw inflammatory hyperalgesia in rats and in an acetic acid induced (10 mg/kg, 0.75%) writhing test in mice. In both models, drugs were coadministered in fixed-dose fractions of the 50% effective dose (ED(50)), and type of interaction was determined by isobolographic analysis. RESULTS: Paracetamol (50-200 mg/kg peroral), oxcarbazepine (40-160 mg/kg peroral), and their combination (1/8, 1/4, 1/3, and 1/2 of a single drug ED(50)) produced a significant, dose-dependent antihyperalgesia in carrageenan-injected rats. In the writhing test in mice, paracetamol (60-180 mg/kg peroral), oxcarbazepine (20-80 mg/kg peroral), and their combination (1/16, 1/8, 1/4, and 1/2 of a single drug ED(50)) significantly and dose dependently reduced the number of writhes. In both models, isobolographic analysis revealed a significant synergistic interaction between paracetamol and oxcarbazepine, with a >4-fold reduction of doses of both drugs in combination, compared with single drugs ED(50). CONCLUSIONS: The, synergistic interaction between paracetamol and oxcarbazepine provides new information about combination pain treatment and should be explored further in patients, especially with somatic and/or visceral pain. (Anesth Analg 2010;110:1198-1205)
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Anesthesia and Analgesia
T1  - Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Models in Rodents
VL  - 110
IS  - 4
SP  - 1198
EP  - 1205
DO  - 10.1213/ANE.0b013e3181cbd8da
ER  - 

@article{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2010",
abstract = "BACKGROUND: Combination therapy is a valid approach in pain treatment, in which a reduction of doses could reduce side effects and still achieve optimal analgesia. We examined the effects of coadministered paracetamol, a widely used non-opioid analgesic, and oxcarbazepine, a relatively novel anticonvulsant with analgesic properties, in a rat model of paw inflammatory hyperalgesia and in a mice model of visceral pain and determined the type of interaction between components. METHODS: The effects of paracetamol, oxcarbazepine, and their combinations were examined in carrageenan-induced (0.1 mL, 1%) paw inflammatory hyperalgesia in rats and in an acetic acid induced (10 mg/kg, 0.75%) writhing test in mice. In both models, drugs were coadministered in fixed-dose fractions of the 50% effective dose (ED(50)), and type of interaction was determined by isobolographic analysis. RESULTS: Paracetamol (50-200 mg/kg peroral), oxcarbazepine (40-160 mg/kg peroral), and their combination (1/8, 1/4, 1/3, and 1/2 of a single drug ED(50)) produced a significant, dose-dependent antihyperalgesia in carrageenan-injected rats. In the writhing test in mice, paracetamol (60-180 mg/kg peroral), oxcarbazepine (20-80 mg/kg peroral), and their combination (1/16, 1/8, 1/4, and 1/2 of a single drug ED(50)) significantly and dose dependently reduced the number of writhes. In both models, isobolographic analysis revealed a significant synergistic interaction between paracetamol and oxcarbazepine, with a >4-fold reduction of doses of both drugs in combination, compared with single drugs ED(50). CONCLUSIONS: The, synergistic interaction between paracetamol and oxcarbazepine provides new information about combination pain treatment and should be explored further in patients, especially with somatic and/or visceral pain. (Anesth Analg 2010;110:1198-1205)",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Anesthesia and Analgesia",
title = "Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Models in Rodents",
volume = "110",
number = "4",
pages = "1198-1205",
doi = "10.1213/ANE.0b013e3181cbd8da"
}

Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Ugrešić, N., Prostran, M.,& Bošković, B.. (2010). Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Models in Rodents. in Anesthesia and Analgesia
Lippincott Williams & Wilkins, Philadelphia., 110(4), 1198-1205.
https://doi.org/10.1213/ANE.0b013e3181cbd8da

Tomić M, Vučković SM, Stepanović-Petrović R, Ugrešić N, Prostran M, Bošković B. Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Models in Rodents. in Anesthesia and Analgesia. 2010;110(4):1198-1205.
doi:10.1213/ANE.0b013e3181cbd8da .

Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Models in Rodents" in Anesthesia and Analgesia, 110, no. 4 (2010):1198-1205,
https://doi.org/10.1213/ANE.0b013e3181cbd8da . .

TY  - CONF
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Stepanović-Petrović, Radica
AU  - Micov, Ana
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1353
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia
VL  - 20
IS  - Supplement 3
SP  - S263
EP  - S263
DO  - 10.1016/S0924-977X(10)70336-9
ER  - 

@conference{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Micov, Ana and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia",
volume = "20",
number = "Supplement 3",
pages = "S263-S263",
doi = "10.1016/S0924-977X(10)70336-9"
}

Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Micov, A., Ugrešić, N., Prostran, M.,& Bošković, B.. (2010). Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S263-S263.
https://doi.org/10.1016/S0924-977X(10)70336-9

Tomić M, Vučković SM, Stepanović-Petrović R, Micov A, Ugrešić N, Prostran M, Bošković B. Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia. in European Neuropsychopharmacology. 2010;20(Supplement 3):S263-S263.
doi:10.1016/S0924-977X(10)70336-9 .

Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Micov, Ana, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S263-S263,
https://doi.org/10.1016/S0924-977X(10)70336-9 . .

TY  - JOUR
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Stepanović-Petrović, Radica
AU  - Micov, Ana
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1387
AB  - Antiepileptic and antidepressant drugs are the primary treatments for pain relief in diabetic neuropathy. Combination therapy is a valid approach in pain treatment, where a reduction of doses could reduce side effects and still achieve optimal analgesia. We examined the effects of two-drug combinations of gabapentin, oxcarbazepine, and amitriptyline on nociception in diabetic mice and aimed to determine the type of interaction between components. The nociceptive responses in normal and diabetic mice were assessed by the tail-flick test. The testing was performed before and three weeks after the diabetes induction with streptozotocin (150 mg/kg; i.p.), when the antinociceptive effects of gabapentin, oxcarbazepine, amitriptyline and their two-drug combinations were examined. Gabapentin (10-40 mg/kg; p.o.) and oxcarbazepine (20-80 mg/kg; p.o.) produced a significant, dose-dependent antinociception in diabetic mice while amitriptyline (5-60 mg/kg; p.o.) produced weak antinociceptive effect. In normal mice, neither of the drugs produced antinociception. Gabapentin and oxcarbazepine, co-administered in fixed-dose fractions of the ED(50) to diabetic mice, induced significant, dose-dependent antinociception. Isobolographic analysis revealed synergistic interaction. Oxcarbazepine (10-60mg/kg; p.o.)+amitriptyline (5mg/kg; p.o.) and gabapentin (10-30mg/kg: p.o.)+amitriptyline (5mg/kg; p.o.) combinations significantly and close-dependently reduced nociception in diabetic mice. Analysis of the log dose-response curves for oxcarbazepine or gabapentin in a presence of amitriptyline and oxcarbazepine or gabapentin applied alone, revealed a synergism in oxcarbazepine-amitriptyline and additivity in gabapentin-amitriptyline combination. These findings provide new information about the combination therapy of painful diabetic neuropathy and should be explored further in patients with diabetic neuropathy.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmacology
T1  - Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice
VL  - 628
IS  - 1-3
SP  - 75
EP  - 82
DO  - 10.1016/j.ejphar.2009.11.016
ER  - 

@article{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Micov, Ana and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2010",
abstract = "Antiepileptic and antidepressant drugs are the primary treatments for pain relief in diabetic neuropathy. Combination therapy is a valid approach in pain treatment, where a reduction of doses could reduce side effects and still achieve optimal analgesia. We examined the effects of two-drug combinations of gabapentin, oxcarbazepine, and amitriptyline on nociception in diabetic mice and aimed to determine the type of interaction between components. The nociceptive responses in normal and diabetic mice were assessed by the tail-flick test. The testing was performed before and three weeks after the diabetes induction with streptozotocin (150 mg/kg; i.p.), when the antinociceptive effects of gabapentin, oxcarbazepine, amitriptyline and their two-drug combinations were examined. Gabapentin (10-40 mg/kg; p.o.) and oxcarbazepine (20-80 mg/kg; p.o.) produced a significant, dose-dependent antinociception in diabetic mice while amitriptyline (5-60 mg/kg; p.o.) produced weak antinociceptive effect. In normal mice, neither of the drugs produced antinociception. Gabapentin and oxcarbazepine, co-administered in fixed-dose fractions of the ED(50) to diabetic mice, induced significant, dose-dependent antinociception. Isobolographic analysis revealed synergistic interaction. Oxcarbazepine (10-60mg/kg; p.o.)+amitriptyline (5mg/kg; p.o.) and gabapentin (10-30mg/kg: p.o.)+amitriptyline (5mg/kg; p.o.) combinations significantly and close-dependently reduced nociception in diabetic mice. Analysis of the log dose-response curves for oxcarbazepine or gabapentin in a presence of amitriptyline and oxcarbazepine or gabapentin applied alone, revealed a synergism in oxcarbazepine-amitriptyline and additivity in gabapentin-amitriptyline combination. These findings provide new information about the combination therapy of painful diabetic neuropathy and should be explored further in patients with diabetic neuropathy.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmacology",
title = "Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice",
volume = "628",
number = "1-3",
pages = "75-82",
doi = "10.1016/j.ejphar.2009.11.016"
}

Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Micov, A., Ugrešić, N., Prostran, M.,& Bošković, B.. (2010). Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice. in European Journal of Pharmacology
Elsevier Science BV, Amsterdam., 628(1-3), 75-82.
https://doi.org/10.1016/j.ejphar.2009.11.016

Tomić M, Vučković SM, Stepanović-Petrović R, Micov A, Ugrešić N, Prostran M, Bošković B. Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice. in European Journal of Pharmacology. 2010;628(1-3):75-82.
doi:10.1016/j.ejphar.2009.11.016 .

Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Micov, Ana, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice" in European Journal of Pharmacology, 628, no. 1-3 (2010):75-82,
https://doi.org/10.1016/j.ejphar.2009.11.016 . .

TY  - CONF
AU  - Milinković, Marija M.
AU  - Savić, Miroslav
AU  - Rallapalli, Sundari
AU  - Samardžić, Janko
AU  - van Linn, Michael
AU  - Ugrešić, Nenad
AU  - Cook, James M.
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1063
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity
VL  - 18
IS  - Supplement 4
SP  - S284
EP  - S284
DO  - 10.1016/S0924-977X(08)70375-4
ER  - 

@conference{
author = "Milinković, Marija M. and Savić, Miroslav and Rallapalli, Sundari and Samardžić, Janko and van Linn, Michael and Ugrešić, Nenad and Cook, James M.",
year = "2008",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity",
volume = "18",
number = "Supplement 4",
pages = "S284-S284",
doi = "10.1016/S0924-977X(08)70375-4"
}

Milinković, M. M., Savić, M., Rallapalli, S., Samardžić, J., van Linn, M., Ugrešić, N.,& Cook, J. M.. (2008). RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 18(Supplement 4), S284-S284.
https://doi.org/10.1016/S0924-977X(08)70375-4

Milinković MM, Savić M, Rallapalli S, Samardžić J, van Linn M, Ugrešić N, Cook JM. RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity. in European Neuropsychopharmacology. 2008;18(Supplement 4):S284-S284.
doi:10.1016/S0924-977X(08)70375-4 .

Milinković, Marija M., Savić, Miroslav, Rallapalli, Sundari, Samardžić, Janko, van Linn, Michael, Ugrešić, Nenad, Cook, James M., "RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity" in European Neuropsychopharmacology, 18, no. Supplement 4 (2008):S284-S284,
https://doi.org/10.1016/S0924-977X(08)70375-4 . .

TY  - JOUR
AU  - Stepanović-Petrović, Radica
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Kocev, Nikola
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1092
AB  - Background/Aims: The purpose of this study was to investigate the involvement of GABAergic mechanisms in the antihyperalgesic effect of carbamazepine and oxcarbazepine by examining the effect of bicuculline ( GABA A receptor antagonist) on these effects of antiepileptic drugs. Methods: Rats were intraplantarly (i.pl.) injected with the proinflammatory compound concanavalin A ( Con A). A paw-pressure test was used to determine: ( 1) the development of hyperalgesia induced by Con A; ( 2) the effects of carbamazepine/ oxcarbazepine on Con A-induced hyperalgesia, and ( 3) the effects of bicuculline on the carbamazepine/ oxcarbazepine antihyperalgesia. Results: Intraperitoneally injected bicuculline (0.5 - 1 mg/kg, i.p.) exhibited significant suppression of the systemic antihyperalgesic effects of carbamazepine ( 27 mg/ kg, i.p.) and oxcarbazepine ( 80 mg/ kg, i.p.). When applied intraplantarly, bicuculline ( 0.14 mg/ paw, i.pl.) did not produce any change in the peripheral antihyperalgesic effects of carbamazepine ( 0.14 mg/ paw, i.pl.) and oxcarbazepine (0.5 mg/paw, i.pl.). Bicuculline alone did not produce an intrinsic effect in the paw-pressure test. Conclusion: These results indicate that the antihyperalgesic effects of carbamazepine and oxcarbazepine against inflammatory hyperalgesia involve in part the GABAergic inhibitory modulation of pain transmission at central, but not at peripheral sites, which is mediated via GABA A receptor activation. Copyright
PB  - Karger, Basel
T2  - Pharmacology
T1  - GABAergic mechanisms are involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory hyperalgesia
VL  - 82
IS  - 1
SP  - 53
EP  - 58
DO  - 10.1159/000127841
ER  - 

@article{
author = "Stepanović-Petrović, Radica and Tomić, Maja and Vučković, Sonja M. and Kocev, Nikola and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2008",
abstract = "Background/Aims: The purpose of this study was to investigate the involvement of GABAergic mechanisms in the antihyperalgesic effect of carbamazepine and oxcarbazepine by examining the effect of bicuculline ( GABA A receptor antagonist) on these effects of antiepileptic drugs. Methods: Rats were intraplantarly (i.pl.) injected with the proinflammatory compound concanavalin A ( Con A). A paw-pressure test was used to determine: ( 1) the development of hyperalgesia induced by Con A; ( 2) the effects of carbamazepine/ oxcarbazepine on Con A-induced hyperalgesia, and ( 3) the effects of bicuculline on the carbamazepine/ oxcarbazepine antihyperalgesia. Results: Intraperitoneally injected bicuculline (0.5 - 1 mg/kg, i.p.) exhibited significant suppression of the systemic antihyperalgesic effects of carbamazepine ( 27 mg/ kg, i.p.) and oxcarbazepine ( 80 mg/ kg, i.p.). When applied intraplantarly, bicuculline ( 0.14 mg/ paw, i.pl.) did not produce any change in the peripheral antihyperalgesic effects of carbamazepine ( 0.14 mg/ paw, i.pl.) and oxcarbazepine (0.5 mg/paw, i.pl.). Bicuculline alone did not produce an intrinsic effect in the paw-pressure test. Conclusion: These results indicate that the antihyperalgesic effects of carbamazepine and oxcarbazepine against inflammatory hyperalgesia involve in part the GABAergic inhibitory modulation of pain transmission at central, but not at peripheral sites, which is mediated via GABA A receptor activation. Copyright",
publisher = "Karger, Basel",
journal = "Pharmacology",
title = "GABAergic mechanisms are involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory hyperalgesia",
volume = "82",
number = "1",
pages = "53-58",
doi = "10.1159/000127841"
}

Stepanović-Petrović, R., Tomić, M., Vučković, S. M., Kocev, N., Ugrešić, N., Prostran, M.,& Bošković, B.. (2008). GABAergic mechanisms are involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory hyperalgesia. in Pharmacology
Karger, Basel., 82(1), 53-58.
https://doi.org/10.1159/000127841

Stepanović-Petrović R, Tomić M, Vučković SM, Kocev N, Ugrešić N, Prostran M, Bošković B. GABAergic mechanisms are involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory hyperalgesia. in Pharmacology. 2008;82(1):53-58.
doi:10.1159/000127841 .

Stepanović-Petrović, Radica, Tomić, Maja, Vučković, Sonja M., Kocev, Nikola, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "GABAergic mechanisms are involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory hyperalgesia" in Pharmacology, 82, no. 1 (2008):53-58,
https://doi.org/10.1159/000127841 . .

TY  - JOUR
AU  - Stepanović-Petrović, Radica
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Paranos, Sonja
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Milovanović, Slobocian
AU  - Bošković, Bogdan
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1067
AB  - BACKGROUND: There is evidence supporting the antinociceptive effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in various models of neuropathic pain as well as inflammatory somatic pain. Data are lacking on the antinociceptive potential of these drugs against visceral pain. In this study, we examined and compared the effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in the writhing test as a visceral pain model in the mouse. In addition, the influence of these anticonvulsants on motor performance was examined to compare the tolerability of these anticonvulsants when used against acute visceral pain. METHODS: The antinociceptive effects of these anticonvulsants were examined in the acetic acid writhing test in mice. The side effect propensity of these drugs was examined using the rotarod test. RESULTS: Carbamazepine (25-60 mg/kg; p.o.), oxcarbazepine (10-40 mg/kg; p.o.), gabapentin (10-70 mg/kg; p.o.), and topiramate (5-30 mg/kg; p.o.) caused a significant dose-dependent reduction the number of writhes in the writhing test. In the rotarod test, carbamazepine (60-140 mg/kg; p.o.) and oxcarbazepine (120-450 mg/kg; p.o.) significantly reduced the time spent on the rotarod in a dose- and time-dependent manner. Gabapentin (1000-2000 mg/kg; p.o.) and topiramate (400-1500 mg/kg; p.o.) did not produce significant impairment of motor performance at the highest doses used. The therapeutic index (motor impairing dose TD50)/writhing ED50) values were topiramate (>148.5) > gabapentin (>60.2) > oxcarbazepine (15.2) > carbamazepine (2.3). CONCLUSIONS: These results indicate that oxcarbazepine, gabapentin, and topiramate are effective in the writhing model in mice, in a dose range, which is not related to motor impairment; topiramate is the most potent and the most tolerable drug.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Anesthesia and Analgesia
T1  - The antinociceptive effects of anticonvulsants in a mouse visceral pain model
VL  - 106
IS  - 6
SP  - 1897
EP  - 1903
DO  - 10.1213/ane.0b013618172b993
ER  - 

@article{
author = "Stepanović-Petrović, Radica and Tomić, Maja and Vučković, Sonja M. and Paranos, Sonja and Ugrešić, Nenad and Prostran, Milica and Milovanović, Slobocian and Bošković, Bogdan",
year = "2008",
abstract = "BACKGROUND: There is evidence supporting the antinociceptive effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in various models of neuropathic pain as well as inflammatory somatic pain. Data are lacking on the antinociceptive potential of these drugs against visceral pain. In this study, we examined and compared the effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in the writhing test as a visceral pain model in the mouse. In addition, the influence of these anticonvulsants on motor performance was examined to compare the tolerability of these anticonvulsants when used against acute visceral pain. METHODS: The antinociceptive effects of these anticonvulsants were examined in the acetic acid writhing test in mice. The side effect propensity of these drugs was examined using the rotarod test. RESULTS: Carbamazepine (25-60 mg/kg; p.o.), oxcarbazepine (10-40 mg/kg; p.o.), gabapentin (10-70 mg/kg; p.o.), and topiramate (5-30 mg/kg; p.o.) caused a significant dose-dependent reduction the number of writhes in the writhing test. In the rotarod test, carbamazepine (60-140 mg/kg; p.o.) and oxcarbazepine (120-450 mg/kg; p.o.) significantly reduced the time spent on the rotarod in a dose- and time-dependent manner. Gabapentin (1000-2000 mg/kg; p.o.) and topiramate (400-1500 mg/kg; p.o.) did not produce significant impairment of motor performance at the highest doses used. The therapeutic index (motor impairing dose TD50)/writhing ED50) values were topiramate (>148.5) > gabapentin (>60.2) > oxcarbazepine (15.2) > carbamazepine (2.3). CONCLUSIONS: These results indicate that oxcarbazepine, gabapentin, and topiramate are effective in the writhing model in mice, in a dose range, which is not related to motor impairment; topiramate is the most potent and the most tolerable drug.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Anesthesia and Analgesia",
title = "The antinociceptive effects of anticonvulsants in a mouse visceral pain model",
volume = "106",
number = "6",
pages = "1897-1903",
doi = "10.1213/ane.0b013618172b993"
}

Stepanović-Petrović, R., Tomić, M., Vučković, S. M., Paranos, S., Ugrešić, N., Prostran, M., Milovanović, S.,& Bošković, B.. (2008). The antinociceptive effects of anticonvulsants in a mouse visceral pain model. in Anesthesia and Analgesia
Lippincott Williams & Wilkins, Philadelphia., 106(6), 1897-1903.
https://doi.org/10.1213/ane.0b013618172b993

Stepanović-Petrović R, Tomić M, Vučković SM, Paranos S, Ugrešić N, Prostran M, Milovanović S, Bošković B. The antinociceptive effects of anticonvulsants in a mouse visceral pain model. in Anesthesia and Analgesia. 2008;106(6):1897-1903.
doi:10.1213/ane.0b013618172b993 .

Stepanović-Petrović, Radica, Tomić, Maja, Vučković, Sonja M., Paranos, Sonja, Ugrešić, Nenad, Prostran, Milica, Milovanović, Slobocian, Bošković, Bogdan, "The antinociceptive effects of anticonvulsants in a mouse visceral pain model" in Anesthesia and Analgesia, 106, no. 6 (2008):1897-1903,
https://doi.org/10.1213/ane.0b013618172b993 . .

TY  - JOUR
AU  - Savić, Miroslav
AU  - Huang, Shengming
AU  - Furtmueller, Roman
AU  - Clayton, Terry
AU  - Huck, Sigismund
AU  - Obradović, Dragan I.
AU  - Ugrešić, Nenad
AU  - Sieghart, Werner
AU  - Bokonjić, Dubravko
AU  - Cook, James M.
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1048
AB  - Classical benzodiazepines (BZs) exert anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsive, and amnesic effects through potentiation of neurotransmission at GABA(A) receptors containing alpha(1), alpha(2), alpha(3) or alpha(5) subunits. Genetic studies suggest that modulation at the alpha(1) subunit contributes to much of the adverse effects of BZs, most notably sedation, ataxia, and amnesia. Hence, BZ site ligands functionally inactive at GABAA receptors containing the alpha(1) subunit are considered to be promising leads for novel, anxioselective anxiolytics devoid of sedative properties. In pursuing this approach, we used two-electrode voltage clamp experiments in Xenopus oocytes expressing recombinant GABAA receptor subtypes to investigate functional selectivity of three newly synthesized BZ site ligands and also compared their in vivo behavioral profiles. The compounds were functionally selective for alpha(2)-, alpha(3)-, and alpha(5)-containing subtypes of GABA(A) receptors (SH-053-S-CH3 and SH-053-S-CH3-2'F) or essentially selective for alpha(5) subtypes (SH-053-R-CH3). Possible influences on behavioral measures were tested in the elevated plus maze, spontaneous locomotor activity, and rotarod test, which are considered primarily predictive of the anxiolytic, sedative, and ataxic influence of BZs, respectively. The results confirmed the substantially diminished ataxic potential of BZ site agonists devoid of alpha(1) subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of SH-053-S-CH3 and SH-053-S-CH3-2'F. However, all three ligands, dosed at 30 mg/kg, decreased spontaneous locomotor activity, suggesting that sedation may be partly dependent on activity mediated by alpha(5)-containing GABAA receptors. Hence, it could be of importance to avoid substantial agonist activity at alpha(5) receptors by candidate anxioselective anxiolytics, if clinical sedation is to be avoided.
PB  - Nature Publishing Group, London
T2  - Neuropsychopharmacology
T1  - Are GABA(A) receptors containing alpha 5 Subunits contributing to the sedative properties of benzodiazepine site agonists?
VL  - 33
IS  - 2
SP  - 332
EP  - 339
DO  - 10.1038/sj.npp.1301403
ER  - 

@article{
author = "Savić, Miroslav and Huang, Shengming and Furtmueller, Roman and Clayton, Terry and Huck, Sigismund and Obradović, Dragan I. and Ugrešić, Nenad and Sieghart, Werner and Bokonjić, Dubravko and Cook, James M.",
year = "2008",
abstract = "Classical benzodiazepines (BZs) exert anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsive, and amnesic effects through potentiation of neurotransmission at GABA(A) receptors containing alpha(1), alpha(2), alpha(3) or alpha(5) subunits. Genetic studies suggest that modulation at the alpha(1) subunit contributes to much of the adverse effects of BZs, most notably sedation, ataxia, and amnesia. Hence, BZ site ligands functionally inactive at GABAA receptors containing the alpha(1) subunit are considered to be promising leads for novel, anxioselective anxiolytics devoid of sedative properties. In pursuing this approach, we used two-electrode voltage clamp experiments in Xenopus oocytes expressing recombinant GABAA receptor subtypes to investigate functional selectivity of three newly synthesized BZ site ligands and also compared their in vivo behavioral profiles. The compounds were functionally selective for alpha(2)-, alpha(3)-, and alpha(5)-containing subtypes of GABA(A) receptors (SH-053-S-CH3 and SH-053-S-CH3-2'F) or essentially selective for alpha(5) subtypes (SH-053-R-CH3). Possible influences on behavioral measures were tested in the elevated plus maze, spontaneous locomotor activity, and rotarod test, which are considered primarily predictive of the anxiolytic, sedative, and ataxic influence of BZs, respectively. The results confirmed the substantially diminished ataxic potential of BZ site agonists devoid of alpha(1) subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of SH-053-S-CH3 and SH-053-S-CH3-2'F. However, all three ligands, dosed at 30 mg/kg, decreased spontaneous locomotor activity, suggesting that sedation may be partly dependent on activity mediated by alpha(5)-containing GABAA receptors. Hence, it could be of importance to avoid substantial agonist activity at alpha(5) receptors by candidate anxioselective anxiolytics, if clinical sedation is to be avoided.",
publisher = "Nature Publishing Group, London",
journal = "Neuropsychopharmacology",
title = "Are GABA(A) receptors containing alpha 5 Subunits contributing to the sedative properties of benzodiazepine site agonists?",
volume = "33",
number = "2",
pages = "332-339",
doi = "10.1038/sj.npp.1301403"
}

Savić, M., Huang, S., Furtmueller, R., Clayton, T., Huck, S., Obradović, D. I., Ugrešić, N., Sieghart, W., Bokonjić, D.,& Cook, J. M.. (2008). Are GABA(A) receptors containing alpha 5 Subunits contributing to the sedative properties of benzodiazepine site agonists?. in Neuropsychopharmacology
Nature Publishing Group, London., 33(2), 332-339.
https://doi.org/10.1038/sj.npp.1301403

Savić M, Huang S, Furtmueller R, Clayton T, Huck S, Obradović DI, Ugrešić N, Sieghart W, Bokonjić D, Cook JM. Are GABA(A) receptors containing alpha 5 Subunits contributing to the sedative properties of benzodiazepine site agonists?. in Neuropsychopharmacology. 2008;33(2):332-339.
doi:10.1038/sj.npp.1301403 .

Savić, Miroslav, Huang, Shengming, Furtmueller, Roman, Clayton, Terry, Huck, Sigismund, Obradović, Dragan I., Ugrešić, Nenad, Sieghart, Werner, Bokonjić, Dubravko, Cook, James M., "Are GABA(A) receptors containing alpha 5 Subunits contributing to the sedative properties of benzodiazepine site agonists?" in Neuropsychopharmacology, 33, no. 2 (2008):332-339,
https://doi.org/10.1038/sj.npp.1301403 . .

TY  - CONF
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Stepanović-Petrović, Radica
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/894
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Synergistic interaction between gabapentin and oxcarbazepine in a mouse model of painful diabetic neuropathy
VL  - 17
IS  - Supplement 4
SP  - S259
EP  - S259
DO  - 10.1016/S0924-977X(07)70354-1
ER  - 

@conference{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2007",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Synergistic interaction between gabapentin and oxcarbazepine in a mouse model of painful diabetic neuropathy",
volume = "17",
number = "Supplement 4",
pages = "S259-S259",
doi = "10.1016/S0924-977X(07)70354-1"
}

Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Ugrešić, N., Prostran, M.,& Bošković, B.. (2007). Synergistic interaction between gabapentin and oxcarbazepine in a mouse model of painful diabetic neuropathy. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 17(Supplement 4), S259-S259.
https://doi.org/10.1016/S0924-977X(07)70354-1

Tomić M, Vučković SM, Stepanović-Petrović R, Ugrešić N, Prostran M, Bošković B. Synergistic interaction between gabapentin and oxcarbazepine in a mouse model of painful diabetic neuropathy. in European Neuropsychopharmacology. 2007;17(Supplement 4):S259-S259.
doi:10.1016/S0924-977X(07)70354-1 .

Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Synergistic interaction between gabapentin and oxcarbazepine in a mouse model of painful diabetic neuropathy" in European Neuropsychopharmacology, 17, no. Supplement 4 (2007):S259-S259,
https://doi.org/10.1016/S0924-977X(07)70354-1 . .

TY  - JOUR
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Stepanović-Petrović, Radica
AU  - Ugrešić, Nenad
AU  - Paranos, Sonja
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/983
AB  - We studied whether peripheral alpha(2)-adrenergic receptors are involved in the antihyperalgesic effects of oxcarbazepine by examining the effects of yohimbine (selective alpha(2)-adrenoceptor antagonist), BRL 44408 (selective alpha(2A)- adrenoceptor antagonist), MK-912 (selective alpha(2C)-adrenoceptor antagonist), and clonidine (alpha(2)-adrenoceptor agonist) on the antihyperalgesic effect of oxcarbazepine in the rat model of inflammatory pain. METHODS: Rats were intraplantarly (i.pl.) injected with the proinflammatory compound concanavalin A (Con A). A paw-pressure test was used to determine: 1) the development of hyperalgesia induced by Con A; 2) the effects of oxcarbazepine (i.pl.) on Con A-induced hyperalgesia; and 3) the effects of i.pl. yohimbine, BRL 44408, MK-912 and clonidine on the oxcarbazepine antihyperalgesia. RESULTS: Both oxcarbazepine (1000-3000 nmol/paw; i.pl.) and clonidine (1.9-7.5 nmol/paw; i.pl.) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia induced by Con A. Yohimbine (260 and 520 nmol/paw; i.. pl.), BRL44408 (100 and 200 nmol/paw,-i.pl.),and MK-912 (10and 20 nmol/paw;i.pl.) significantly depressed the antihyperalgesic effects of oxcarbazepine (2000 nmol/pav\T,I i.pl.) in a close-dependent mariner. The effects of antagonists were due to local effects since they were not observed after admirdstration into the contralateral hindpaw. Oxcarbazepine and clonidine administered jointly in fixed-dose fractions of the ED50 (1/4, 1/2, and 3/4) caused significant and dose-dependent reduction of hyperalgesia induced by Con A. lsobolographic analysis revealed an additive antihyperalgesic effect. CONCLUSIONS: Our results indicate that the peripheral a,A and a,c adrenoceptors could be involved in the antihyperalgesic effects of oxcarbazepine in a rat model of inflammatory hyperalgesia. (Anesth Analg 2007;105:1474-81)
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Anesthesia and Analgesia
T1  - The involvement of peripheral alpha(2)-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain
VL  - 105
IS  - 5
SP  - 1474
EP  - 1481
DO  - 10.1213/01.ane.0000287270.35176.3e
ER  - 

@article{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Ugrešić, Nenad and Paranos, Sonja and Prostran, Milica and Bošković, Bogdan",
year = "2007",
abstract = "We studied whether peripheral alpha(2)-adrenergic receptors are involved in the antihyperalgesic effects of oxcarbazepine by examining the effects of yohimbine (selective alpha(2)-adrenoceptor antagonist), BRL 44408 (selective alpha(2A)- adrenoceptor antagonist), MK-912 (selective alpha(2C)-adrenoceptor antagonist), and clonidine (alpha(2)-adrenoceptor agonist) on the antihyperalgesic effect of oxcarbazepine in the rat model of inflammatory pain. METHODS: Rats were intraplantarly (i.pl.) injected with the proinflammatory compound concanavalin A (Con A). A paw-pressure test was used to determine: 1) the development of hyperalgesia induced by Con A; 2) the effects of oxcarbazepine (i.pl.) on Con A-induced hyperalgesia; and 3) the effects of i.pl. yohimbine, BRL 44408, MK-912 and clonidine on the oxcarbazepine antihyperalgesia. RESULTS: Both oxcarbazepine (1000-3000 nmol/paw; i.pl.) and clonidine (1.9-7.5 nmol/paw; i.pl.) produced a significant dose-dependent reduction of the paw inflammatory hyperalgesia induced by Con A. Yohimbine (260 and 520 nmol/paw; i.. pl.), BRL44408 (100 and 200 nmol/paw,-i.pl.),and MK-912 (10and 20 nmol/paw;i.pl.) significantly depressed the antihyperalgesic effects of oxcarbazepine (2000 nmol/pav\T,I i.pl.) in a close-dependent mariner. The effects of antagonists were due to local effects since they were not observed after admirdstration into the contralateral hindpaw. Oxcarbazepine and clonidine administered jointly in fixed-dose fractions of the ED50 (1/4, 1/2, and 3/4) caused significant and dose-dependent reduction of hyperalgesia induced by Con A. lsobolographic analysis revealed an additive antihyperalgesic effect. CONCLUSIONS: Our results indicate that the peripheral a,A and a,c adrenoceptors could be involved in the antihyperalgesic effects of oxcarbazepine in a rat model of inflammatory hyperalgesia. (Anesth Analg 2007;105:1474-81)",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Anesthesia and Analgesia",
title = "The involvement of peripheral alpha(2)-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain",
volume = "105",
number = "5",
pages = "1474-1481",
doi = "10.1213/01.ane.0000287270.35176.3e"
}

Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Ugrešić, N., Paranos, S., Prostran, M.,& Bošković, B.. (2007). The involvement of peripheral alpha(2)-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain. in Anesthesia and Analgesia
Lippincott Williams & Wilkins, Philadelphia., 105(5), 1474-1481.
https://doi.org/10.1213/01.ane.0000287270.35176.3e

Tomić M, Vučković SM, Stepanović-Petrović R, Ugrešić N, Paranos S, Prostran M, Bošković B. The involvement of peripheral alpha(2)-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain. in Anesthesia and Analgesia. 2007;105(5):1474-1481.
doi:10.1213/01.ane.0000287270.35176.3e .

Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Ugrešić, Nenad, Paranos, Sonja, Prostran, Milica, Bošković, Bogdan, "The involvement of peripheral alpha(2)-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain" in Anesthesia and Analgesia, 105, no. 5 (2007):1474-1481,
https://doi.org/10.1213/01.ane.0000287270.35176.3e . .

TY  - JOUR
AU  - Stepanović-Petrović, Radica
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, B
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/924
AB  - The mechanisms of the analgesic action of carbamazepine and oxcarbazepine, in particular the role of opioid receptors, have not been established precisely. The systemic effects of naloxone, an opioid receptor antagonist, on the antihyperalgesic effects of carbamazepine and oxcarbazepine were examined in the model of inflammatory hyperalgesia induced by the intraplantar (i.pl.) administration of concanavaline A (Con A, 0.8 mg/paw) into the rat hind paw. Naloxone (3 mg/kg; i.p.) did not alter the antihyperalgesic effects of either carbamazepine or axcarbazepine. These results indicate that the opioid system of pain modulation does not play a significant role in the antihyperalgesic effects of carbamazepine and oxcarbazepine.
PB  - Prous Science, Sau-Thomson Reuters, Barcelona
T2  - Methods and Findings in Experimental and Clinical Pharmacology
T1  - Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine
VL  - 29
IS  - 3
SP  - 191
EP  - 194
DO  - 10.1358/mf.2007.29.3.1075352
ER  - 

@article{
author = "Stepanović-Petrović, Radica and Tomić, Maja and Vučković, Sonja M. and Ugrešić, Nenad and Prostran, Milica and Bošković, B",
year = "2007",
abstract = "The mechanisms of the analgesic action of carbamazepine and oxcarbazepine, in particular the role of opioid receptors, have not been established precisely. The systemic effects of naloxone, an opioid receptor antagonist, on the antihyperalgesic effects of carbamazepine and oxcarbazepine were examined in the model of inflammatory hyperalgesia induced by the intraplantar (i.pl.) administration of concanavaline A (Con A, 0.8 mg/paw) into the rat hind paw. Naloxone (3 mg/kg; i.p.) did not alter the antihyperalgesic effects of either carbamazepine or axcarbazepine. These results indicate that the opioid system of pain modulation does not play a significant role in the antihyperalgesic effects of carbamazepine and oxcarbazepine.",
publisher = "Prous Science, Sau-Thomson Reuters, Barcelona",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
title = "Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine",
volume = "29",
number = "3",
pages = "191-194",
doi = "10.1358/mf.2007.29.3.1075352"
}

Stepanović-Petrović, R., Tomić, M., Vučković, S. M., Ugrešić, N., Prostran, M.,& Bošković, B.. (2007). Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine. in Methods and Findings in Experimental and Clinical Pharmacology
Prous Science, Sau-Thomson Reuters, Barcelona., 29(3), 191-194.
https://doi.org/10.1358/mf.2007.29.3.1075352

Stepanović-Petrović R, Tomić M, Vučković SM, Ugrešić N, Prostran M, Bošković B. Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine. in Methods and Findings in Experimental and Clinical Pharmacology. 2007;29(3):191-194.
doi:10.1358/mf.2007.29.3.1075352 .

Stepanović-Petrović, Radica, Tomić, Maja, Vučković, Sonja M., Ugrešić, Nenad, Prostran, Milica, Bošković, B, "Opioidergic mechanisms are not involved in the antihyperalgesic effects of carbamazepine and oxcarbazepine" in Methods and Findings in Experimental and Clinical Pharmacology, 29, no. 3 (2007):191-194,
https://doi.org/10.1358/mf.2007.29.3.1075352 . .

TY  - JOUR
AU  - Vučković, Sonja M.
AU  - Tomić, Maja
AU  - Stepanović-Petrović, Radica
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/904
AB  - The anticonvulsant carbamazepine was recently shown to possess local peripheral antinociceptive properties. In this study, we investigated whether alpha 2-adrenergic receptors are involved in the local peripheral antihyperalgesic effects of carbamazepine and determined the type of interaction between carbamazepine and clonidine, an alpha 2-adrenoceptor agonist. Intraplantar (i.pl.) coadministration of either carbamazepine (100-1000 nmol/paw) or clonidine (1.9-3.7 nmol/paw) with the proinflammatory compound concanavalin A (Con A; 0.8 mg/paw) caused a significant dose- and time-dependent reduction of the difference between the forces exerted by a rat's hind paws in a modified paw-pressure test. The coadministration of 260 and 520 nmol/paw (i.pl.) yohimbine, an alpha 2-adrenoceptor antagonist, with carbamazepine, significantly depressed the local antihyperalgesic effect in a dose- and time-dependent manner whereas yohimbine by itself did not have any effect. The administration of a mixture of carbamazepine and clonidine at fixed dose fractions (114, 112 and 314) of ED50 caused a significant and dose-dependent reduction of Con A-induced hyperalgesia. Isobolographic analysis revealed an additive interaction. These results suggest that alpha 2-adrenoceptors play a role in the local peripheral antihyperalgesic effects of carbamazepine and that local peripheral coadministration of carbamazepine with clonidine results in an additive antihyperalgesic effect.
PB  - Prous Science, Sa, Barcelona
T2  - Methods and Findings in Experimental and Clinical Pharmacology
T1  - Role of alpha 2-adrenoceptors in the local peripheral antinociception by carbamazepine in a rat model of inflammatory mechanical hyperalgesia
VL  - 29
IS  - 10
SP  - 689
EP  - 696
DO  - 10.1358/mf.2007.29.10.1147773
ER  - 

@article{
author = "Vučković, Sonja M. and Tomić, Maja and Stepanović-Petrović, Radica and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2007",
abstract = "The anticonvulsant carbamazepine was recently shown to possess local peripheral antinociceptive properties. In this study, we investigated whether alpha 2-adrenergic receptors are involved in the local peripheral antihyperalgesic effects of carbamazepine and determined the type of interaction between carbamazepine and clonidine, an alpha 2-adrenoceptor agonist. Intraplantar (i.pl.) coadministration of either carbamazepine (100-1000 nmol/paw) or clonidine (1.9-3.7 nmol/paw) with the proinflammatory compound concanavalin A (Con A; 0.8 mg/paw) caused a significant dose- and time-dependent reduction of the difference between the forces exerted by a rat's hind paws in a modified paw-pressure test. The coadministration of 260 and 520 nmol/paw (i.pl.) yohimbine, an alpha 2-adrenoceptor antagonist, with carbamazepine, significantly depressed the local antihyperalgesic effect in a dose- and time-dependent manner whereas yohimbine by itself did not have any effect. The administration of a mixture of carbamazepine and clonidine at fixed dose fractions (114, 112 and 314) of ED50 caused a significant and dose-dependent reduction of Con A-induced hyperalgesia. Isobolographic analysis revealed an additive interaction. These results suggest that alpha 2-adrenoceptors play a role in the local peripheral antihyperalgesic effects of carbamazepine and that local peripheral coadministration of carbamazepine with clonidine results in an additive antihyperalgesic effect.",
publisher = "Prous Science, Sa, Barcelona",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
title = "Role of alpha 2-adrenoceptors in the local peripheral antinociception by carbamazepine in a rat model of inflammatory mechanical hyperalgesia",
volume = "29",
number = "10",
pages = "689-696",
doi = "10.1358/mf.2007.29.10.1147773"
}

Vučković, S. M., Tomić, M., Stepanović-Petrović, R., Ugrešić, N., Prostran, M.,& Bošković, B.. (2007). Role of alpha 2-adrenoceptors in the local peripheral antinociception by carbamazepine in a rat model of inflammatory mechanical hyperalgesia. in Methods and Findings in Experimental and Clinical Pharmacology
Prous Science, Sa, Barcelona., 29(10), 689-696.
https://doi.org/10.1358/mf.2007.29.10.1147773

Vučković SM, Tomić M, Stepanović-Petrović R, Ugrešić N, Prostran M, Bošković B. Role of alpha 2-adrenoceptors in the local peripheral antinociception by carbamazepine in a rat model of inflammatory mechanical hyperalgesia. in Methods and Findings in Experimental and Clinical Pharmacology. 2007;29(10):689-696.
doi:10.1358/mf.2007.29.10.1147773 .

Vučković, Sonja M., Tomić, Maja, Stepanović-Petrović, Radica, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Role of alpha 2-adrenoceptors in the local peripheral antinociception by carbamazepine in a rat model of inflammatory mechanical hyperalgesia" in Methods and Findings in Experimental and Clinical Pharmacology, 29, no. 10 (2007):689-696,
https://doi.org/10.1358/mf.2007.29.10.1147773 . .

TY  - CONF
AU  - Stepanović-Petrović, Radica
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, B
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/836
PB  - Blackwell Publishing, Oxford
C3  - Acta Pharmacologica Sinica
T1  - The examination of antinociceptive and toxic effects of oxcarbazepine and carbamazepine in mice
VL  - 27
IS  - Supplement 1
SP  - 86
EP  - 87
UR  - https://hdl.handle.net/21.15107/rcub_farfar_836
ER  - 

@conference{
author = "Stepanović-Petrović, Radica and Tomić, Maja and Vučković, Sonja M. and Ugrešić, Nenad and Prostran, Milica and Bošković, B",
year = "2006",
publisher = "Blackwell Publishing, Oxford",
journal = "Acta Pharmacologica Sinica",
title = "The examination of antinociceptive and toxic effects of oxcarbazepine and carbamazepine in mice",
volume = "27",
number = "Supplement 1",
pages = "86-87",
url = "https://hdl.handle.net/21.15107/rcub_farfar_836"
}

Stepanović-Petrović, R., Tomić, M., Vučković, S. M., Ugrešić, N., Prostran, M.,& Bošković, B.. (2006). The examination of antinociceptive and toxic effects of oxcarbazepine and carbamazepine in mice. in Acta Pharmacologica Sinica
Blackwell Publishing, Oxford., 27(Supplement 1), 86-87.
https://hdl.handle.net/21.15107/rcub_farfar_836

Stepanović-Petrović R, Tomić M, Vučković SM, Ugrešić N, Prostran M, Bošković B. The examination of antinociceptive and toxic effects of oxcarbazepine and carbamazepine in mice. in Acta Pharmacologica Sinica. 2006;27(Supplement 1):86-87.
https://hdl.handle.net/21.15107/rcub_farfar_836 .

Stepanović-Petrović, Radica, Tomić, Maja, Vučković, Sonja M., Ugrešić, Nenad, Prostran, Milica, Bošković, B, "The examination of antinociceptive and toxic effects of oxcarbazepine and carbamazepine in mice" in Acta Pharmacologica Sinica, 27, no. Supplement 1 (2006):86-87,
https://hdl.handle.net/21.15107/rcub_farfar_836 .

TY  - CONF
AU  - Tomić, Maja
AU  - Vučković, Sonja M.
AU  - Stepanović-Petrović, Radica
AU  - Ugrešić, Nenad
AU  - Prostran, Milica
AU  - Bošković, Bogdan
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/715
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Involvement of A1 adenosine and α2 adrenergic receptors in the analgesic effect of carbamazepine and oxcarbazepine in a rat model of inflammatory pain
T1  - Analgetičko dejstvo karbamazepina i okskarbazepina u modelu zapaljenskog bola u pacova ostvaruje se posredstvom A1 adenozinskih i A2 adrenergičkih receptora
VL  - 56
IS  - 4
SP  - 384
EP  - 385
UR  - https://hdl.handle.net/21.15107/rcub_farfar_715
ER  - 

@conference{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2006",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Involvement of A1 adenosine and α2 adrenergic receptors in the analgesic effect of carbamazepine and oxcarbazepine in a rat model of inflammatory pain, Analgetičko dejstvo karbamazepina i okskarbazepina u modelu zapaljenskog bola u pacova ostvaruje se posredstvom A1 adenozinskih i A2 adrenergičkih receptora",
volume = "56",
number = "4",
pages = "384-385",
url = "https://hdl.handle.net/21.15107/rcub_farfar_715"
}

Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Ugrešić, N., Prostran, M.,& Bošković, B.. (2006). Involvement of A1 adenosine and α2 adrenergic receptors in the analgesic effect of carbamazepine and oxcarbazepine in a rat model of inflammatory pain. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(4), 384-385.
https://hdl.handle.net/21.15107/rcub_farfar_715

Tomić M, Vučković SM, Stepanović-Petrović R, Ugrešić N, Prostran M, Bošković B. Involvement of A1 adenosine and α2 adrenergic receptors in the analgesic effect of carbamazepine and oxcarbazepine in a rat model of inflammatory pain. in Arhiv za farmaciju. 2006;56(4):384-385.
https://hdl.handle.net/21.15107/rcub_farfar_715 .

Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Involvement of A1 adenosine and α2 adrenergic receptors in the analgesic effect of carbamazepine and oxcarbazepine in a rat model of inflammatory pain" in Arhiv za farmaciju, 56, no. 4 (2006):384-385,
https://hdl.handle.net/21.15107/rcub_farfar_715 .